Profile Response Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com


Molecular Profile CD274 positive
Therapy Atezolizumab + Carboplatin + Gemcitabine
Indication/Tumor Type triple-receptor negative breast cancer
Response Type no benefit

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
CD274 positive triple-receptor negative breast cancer no benefit Atezolizumab + Carboplatin + Gemcitabine Phase III Actionable In a Phase III trial (Impassion132), the addition of Tecentriq (atezolizumab) to Xeloda (capecitabine) or Paraplatin (carboplatin) plus Gemzar (gemcitabine) treatment did not improve efficacy in early relapsing, unresectable, advanced CD274 (PD-L1)-positive triple-negative breast cancer patients, with median overall survival of 12.1 vs. 11.2 mo (HR=0.93, p=0.59), median progression-free survival of 4.2 vs. 3.6 mo, and objective response rates of 40% (61/177) vs. 28% (45/177) (PMID: 38755096; NCT03371017). 38755096
PubMed Id Reference Title Details
(38755096) IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer. Full reference...